Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,331Revenue $M71.9Net Margin (%)-60.1Altman Z-Score17.3
Enterprise Value $M5,173EPS $-0.8Operating Margin %-142.2Piotroski F-Score2
P/E(ttm)--Beneish M-Score4.2Pre-tax Margin (%)-64.0Higher ROA y-yN
Price/Book7.810-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales48.45-y EBITDA Growth Rate %--Current Ratio4.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-9.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-13.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M109ROIC % (ttm)-49.1Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONFirst Eagle Investment 2015-03-31 Add$26.08 - $50.16
($37.59)
$ 45.9522%Add 4.84%828,104
XONT Boone Pickens 2014-12-31 Buy 0.53%$16.61 - $28.02
($23.05)
$ 45.9599%New holding10,000
XONDavid Einhorn 2014-12-31 Sold Out -0.05%$16.61 - $28.02
($22.97)
$ 45.95100%Sold Out0
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
($21.29)
$ 45.95116%Reduce 47.39%197,278
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
($21.15)
$ 45.95117%Reduce 72.81%375,000
XONFirst Eagle Investment 2014-06-30 Buy 0.04%$15.3 - $25.93
($21.15)
$ 45.95117%New holding661,564
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
($28.82)
$ 45.9559%Reduce 37.58%1,379,014
XONT Boone Pickens 2013-12-31 Sold Out -0.47%$17.65 - $25.5
($21.05)
$ 45.95118%Sold Out0
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
($24.16)
$ 45.9590%New holding2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
($24.16)
$ 45.9590%New holding12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$2770.19view
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.19202.5view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.99187.37view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.6194.55view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.21223.36view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.21223.36view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.39243.17view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.78191.19view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.16203.1view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.7278.65view

Quarterly/Annual Reports about XON:

News about XON:

Articles On GuruFocus.com
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers Jun 29 2015
Fibrocell Joins the Russell 2000(R) Index Jun 29 2015
Intrexon, Enanta Among Top Biotech New Issues Jun 24 2015
Soligenix Announces Collaboration with the National Organization for Rare Disorders and the... Jun 23 2015
INTREXON CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Jun 18 2015
INTREXON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... Jun 17 2015
Intrexon Forms Multi-Year Collaboration with New Dedicated Fund Jun 15 2015
Intrexon Forms Multi-Year Collaboration with New Dedicated Fund Jun 15 2015
First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the... Jun 12 2015
Here’s why some investors think Ziopharm is poised for a $10B merger Jun 11 2015
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral... Jun 10 2015
June 10, 2015 - Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics... Jun 10 2015
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral... Jun 10 2015
Intrexon, Fibrocell Announce Positive Pre-Clinical Data - Analyst Blog Jun 09 2015
Coverage initiated on Intrexon by Wunderlich Jun 09 2015
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of... Jun 08 2015
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of... Jun 08 2015
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares Jun 05 2015
INTREXON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 05 2015
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares Jun 05 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK